Open AccessThe momentum of HeartMate 3: a novel active magnetically levitated centrifugal left ventricular assist device (LVAD)
Author(s) -
Arijit Chatterjee,
C. Feldmann,
Jasmin S. Hanke,
Marcel Ricklefs,
Malakh Shrestha,
G. Dogan,
Axel Haverich,
Jan D. Schmitto
Publication year - 2018
Publication title -
journal of thoracic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 60
eISSN - 2077-6624
pISSN - 2072-1439
DOI - 10.21037/jtd.2017.10.124
Subject(s) - medicine , ventricular assist device , heart failure , destination therapy , cardiology , heart transplantation , bridge to transplantation , transplantation , artificial heart , hemodynamics
Left ventricular assist devices (LVADs) are emerging as the treatment of choice for advanced heart failure due to the dearth of healthy donor hearts for cardiac transplantation. The HeartMate 3 LVAD is a novel centrifugal pump which was developed to provide hemodynamic support in heart failure patients, either as a bridge to transplant (BTT), myocardial recovery, or as destination therapy (DT). Technological and clinical advancements have led to optimized hemocompatibility and development of less invasive surgical procedures for the implantation of this pump. The worldwide first implantation of the HeartMate 3 was performed by Prof. Schmitto and his team at Hannover Medical School, Germany in 2014, paving the way for subsequent surgical developments. This article summarizes the advanced technological and clinical aspects of the HeartMate 3 and outlines future technical developments for safe and effective treatment of advanced heart failure.